Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18139666 | 1.00 | CYP2D6 (0.47) | CYP2D6LMNASPHK1MAPTHTT | |
| SCHEMBL9623258 | 1.00 | CYP2D6 (0.47) | CYP2D6LMNASPHK1MAPTHTT | |
| SCHEMBL29064944 | 1.00 | CYP2D6 (0.47) | CYP2D6LMNASPHK1MAPTHTT | |
| SCHEMBL28434701 | 1.00 | CYP2D6 (0.47) | CYP2D6LMNASPHK1MAPTHTT | |
| SCHEMBL5963213 | 1.00 | CYP2D6 (0.47) | CYP2D6LMNASPHK1MAPTHTT | |
| SCHEMBL8636200 | 1.00 | CYP2D6 (0.47) | CYP2D6LMNASPHK1MAPTHTT | |
| SCHEMBL1890335 | 1.00 | CYP2D6 (0.47) | CYP2D6LMNASPHK1MAPTHTT | |
| SCHEMBL2385585 | 1.00 | CYP2D6 (0.47) | CYP2D6LMNASPHK1MAPTHTT | |
| SCHEMBL142856 | 1.00 | CYP2D6 (0.47) | CYP2D6LMNASPHK1MAPTHTT | |
| SCHEMBL28230194 | 1.00 | CYP2D6 (0.47) | CYP2D6LMNASPHK1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598764-B | Ionizable lipid compounds, compositions and uses | 合肥达徽基因科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119661831-A | Compositions and methods for targeted RNA delivery | 维乎医疗有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119343153-A | Nucleic acid medicine for treating hyperuricemia related diseases and preparation method and application thereof | 北京炫景瑞医药科技有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-119285490-A | Cationic lipid compound, preparation method thereof, composition containing cationic lipid compound and application of cationic lipid compound | 天津全和诚科技有限责任公司 | 2025-01-10 | — | — | CN | claimed |
| CN-117384055-B | Ionizable lipids for delivery of therapeutic agents and uses thereof | 仁景(苏州)生物科技有限公司 | 2024-11-19 | — | — | CN | claimed |
| WO-2024222243-A1 | IONIZABLE LIPID FOR DELIVERY OF THERAPEUTIC AGENT AND USE THEREOF | 仁景(苏州)生物科技有限公司 | 2024-10-31 | — | — | WO | claimed |
| CN-118845700-A | Lipid nanoparticle for delivering nucleic acid drug, preparation method and application thereof | 康希诺(上海)生物研发有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118813629-A | MRNA for expressing aquaporin AQP3 and application thereof | 北京键凯科技股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118767154-A | Multi-arm polyethylene glycol drug conjugate and application thereof | 北京键凯科技股份有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-116211803-B | Inhibiting ataxia telangiectasia and Rad3 associated protein (ATR) | 赛莱特制药公司 | 2024-10-11 | — | — | CN | claimed |
| CN-104382853-A | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MARINA BIOTECH INC | 2015-03-04 | — | — | CN | claimed |
| US-20150024033-A1 | METHOD AND SYSTEM FOR SYNTHESIZING NANOCARRIER BASED LONG ACTING DRUG DELIVERY SYSTEM FOR BUPRENORPHINE | Kimia Zist Parsian Co (IR) | 2015-01-22 | — | — | US | claimed |
| US-20150024035-A1 | METHOD AND SYSTEM FOR SYNTHESIZING NANOCARRIER BASED LONG ACTING DRUG DELIVERY SYSTEM FOR METHADONE | Kimia Zist Parsian Co (IR) | 2015-01-22 | — | — | US | claimed |
| US-20150024034-A1 | METHOD AND SYSTEM FOR SYNTHESIZING NANOCARRIER BASED LONG ACTING DRUG DELIVERY SYSTEM FOR DEXAMETHASONE | Kimia Zist Parsian Co (IR) | 2015-01-22 | — | — | US | claimed |
| US-20140163213-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | COLEY PHARMACEUTICAL GMBH (DE) | 2014-06-12 | — | — | US | claimed |
| EP-2057904-B1 | Structured lipid compositions | KRAFT FOODS GLOBAL BRANDS LLC (US) | 2012-04-25 | — | — | EP | claimed |
| WO-2011119058-A2 | F3-PEPTIDE TARGETED LIPID-BASED NANOPARTICLES USEFUL FOR THE TREATMENT OF ANGIOGENESIS-DEPENDENT DISEASES | UNIVERSIDADE DE COIMBRA (PT) | 2011-09-29 | — | — | WO | claimed |
| US-20100166780-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | PFIZER INC | 2010-07-01 | — | — | US | claimed |
| EP-2078080-A2 | CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | Coley Pharmaceuticals GmbH (DE) | 2009-07-15 | — | — | EP | claimed |
| WO-2008068638-A2 | CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | COLEY PHARMACEUTICAL GMBH (DE) | 2008-06-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150024033-A1 | METHOD AND SYSTEM FOR SYNTHESIZING NANOCARRIER BASED LONG ACTING DRUG DELIVERY SYSTEM FOR BUPRENORPHINE | SIGMAR1, LIPC, LIPA | CYP2D6 5/4885LMNA 348/4885SPHK1 800/4885 |
| US-20150024035-A1 | METHOD AND SYSTEM FOR SYNTHESIZING NANOCARRIER BASED LONG ACTING DRUG DELIVERY SYSTEM FOR METHADONE | SIGMAR1, CETP, LIPA | CYP2D6 6/4885LMNA 463/4885SPHK1 1902/4885 |
| US-20150024034-A1 | METHOD AND SYSTEM FOR SYNTHESIZING NANOCARRIER BASED LONG ACTING DRUG DELIVERY SYSTEM FOR DEXAMETHASONE | STARD3, LIPA, NR3C1 | CYP2D6 58/4885LMNA 257/4885SPHK1 1013/4885 |
| US-20100166780-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | TLR9, TYMP, STING1 | CYP2D6 3105/4885LMNA 4419/4885SPHK1 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.